Navigation Links
VIVUS to Present at Three Upcoming Investor Conferences in March
Date:2/25/2011

MOUNTAIN VIEW, Calif., Feb. 25, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investment conferences during the month of March.  The conference presentation schedule is as follows:Citi's 2011 Global Health Care ConferenceMarch 1, 2011 at 4:00 p.m. ETHilton New York Hotel, New York, NYCowen and Company 31st Annual Health Care ConferenceMarch 8, 2011 at 8:45 a.m. ETThe Boston Marriott Copley Place, Boston, MAROTH Capital Partners 23rd Annual OC Growth Stock ConferenceMarch 15, 2011 at 11:30 a.m. PTRitz-Carlton, Laguna Niguel, CAA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA NDA
2. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
3. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
4. VIVUS to Present at Two Upcoming Investor Conferences
5. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. VIVUS Announces Sale of MUSE Assets to Meda
8. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
9. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
10. VIVUS to Present at Lazard Capital Markets Healthcare Conference
11. VIVUS Announces Promotion of Peter Tam to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... TOKYO , March 29, 2017  The ... unique Japanese public-private partnership formed to battle infectious ... investments totaling US$23 million* that could help deliver ... host of debilitating conditions. This ... a Phase 3 clinical trial testing a pediatric ...
(Date:3/29/2017)... leader in accelerated orthodontics, OrthoAccel ® Technologies, Inc. ... Manal Ibrahim , Kenji Ojima , Ivan ... microlecture presenters at the AcceleDent ® booth (#3037) ... Session, April 21-25, 2017. Orthodontists and their staff are ... a.m. On the opening morning of AAO exhibitions, Sat., ...
(Date:3/29/2017)... 2017 Transparency Market Research ... an exhaustive study of the U.S. substance abuse treatment ... are functional in this market at present, making ... companies, such as GlaxoSmithKline Plc., Pfizer Inc., Alkermes ... various marketing strategies to increase their visibility, the ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale price ... the remaining days of March, the price will be only $19.97. The EXOUS Bodygear ... just $10 (regular retail price $19.97). , The special promotional prices are to help ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
Breaking Medicine News(10 mins):